Intention to treat outcome of T1 hepatocellular carcinoma with the "wait and not ablate" approach until meeting T2 criteria for liver transplant listing
Intention to treat outcome of T1 hepatocellular carcinoma with the "wait and not ablate" approach until meeting T2 criteria for liver transplant listing
复制标题
DOI：
10.1002/lt.24360
复制
发表时间：
2016-02-01
影响因子：
4.6
通讯作者：
Yao, Francis Y.
中科院分区：
文献类型：
--
作者：
Mehta, Neil;Sarkar, Monika;Yao, Francis Y.
T1 肝细胞癌（HCC；1 个病灶肿瘤总直径在 3 个月内增加 1 cm）患者包括酒精性肝病（优势比 [OR]，6.52；P=0.02）和西班牙裔（OR，3.86；P=0.047），而乙型肝炎似乎具有保护性（OR，0.09；P=0.04）。 回归，排除 LT（在 T2 下列出或不列出 LT）的预测因子为甲胎蛋白 (AFP)500ng/mL（HR，12.69；95% 置信区间，2.8-57.0；P=0.001）和肿瘤快速进展（HR，5.68；P）
Patients with T1 hepatocellular carcinoma (HCC; 1 lesion1 cm increase in total tumor diameter over 3 months, included alcoholic liver disease (odds ratio [OR], 6.52; P=0.02) and Hispanic race (OR, 3.86; P=0.047), whereas hepatitis B appeared to be protective (OR, 0.09; P=0.04). By competing risks regression, predictors of exclusion from LT (with or without listing for LT under T2) were alpha-fetoprotein (AFP)500ng/mL (HR, 12.69; 95% confidence interval, 2.8-57.0; P=0.001) and rapid tumor progression (HR, 5.68; P